PQE Group Creates an Internal Research Task Force to Fight Fake News in Relation to COVID-19

FLORENCE, Italy, July 13, 2020 /PRNewswire/ -- With the pandemic caused by COVID-19, the continuous need to obtain information has pushed people to rely on unreliable sources, thus fomenting thespread of fake news. For this reason Gilda D'Incerti, CEO and founder of PQE Group

2020-07-13 16:00 1006

World's First FDA IDE Coronary Patient Treated With a DEB

NYON, Switzerland, July 11, 2020 /PRNewswire/ --  MedAlliance has announced enrollment of the first patient in its study ofSELUTION SLR™ 014 DEB  for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthrough Progr...

2020-07-11 08:00 1884

Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study

STOCKHOLM, July 10, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a positive top line result for the company's pivotal phase III study, IsoConDa. The study reached its primary endpoint; to show that IsoConDa (isoflurane), administered with AnaConDa, is an ef...

2020-07-10 13:32 961

PolyU discovers the effect of chemical compound PTU on autophagy in zebrafish embryos, sheds light on cancer medication research

HONG KONG, July 10, 2020 /PRNewswire/ -- The zebrafish has been utilised as a model organism for biomedical research globally for half a century, mainly due to the high genetic similarity (over 70%) between zebrafish and human genes, with over 80% of human morbid genes related to at least one zeb...

2020-07-10 10:18 995

AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program

SEATTLE, July 9, 2020 /PRNewswire/ -- Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO)AGC Biologics is partnering with clinical-stage biotech companyMolecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Biologics...

2020-07-09 13:00 1106

Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China

SUZHOU, China, July 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today anno...

2020-07-09 08:00 10146

Paige Applauded by Frost & Sullivan for its Leading AI-based Computational Pathology Offering that Enables Fast and Accurate Cancer Diagnoses

Paige leveraged the world's largest dataset in pathology to develop an unparalleled computation pathology offering SANTA CLARA, California, July 8, 2020 /PRNewswire/ -- Based on its recent analysis of the North American AI-based digital pathology market, Frost & Sullivan recognizesPaige with the...

2020-07-08 23:40 1122

Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis

STOCKHOLM, July 8, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to c...

2020-07-08 14:57 917

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China

SHANGHAI, July 8, 2020 /PRNewswire/ -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced an...

2020-07-08 11:37 810

Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment

* Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF * Key milestone and validation for Evive's novel biologic development capability and technology platform * Key component of the asset's BLA submission to receive re...

2020-07-08 09:00 1018

A Breakthrough in Cancer Treatment: Soundny Presents a New Drug-based Alternative in Fight Against Cancer

WUHAN, China, July 7, 2020 /PRNewswire/ -- Hubei Soundny Biotechnology ("Soundny" or the "Company"), a leading biotechnology company dedicated to developing cancer treatments, has published its latest findings on cholangiocarcinoma in Nature Biomedical Engineering, a Nature publication. The rese...

2020-07-07 18:09 490

Genesis Healthcare Co. launched 'GeneLife Generations', a New Ancestry Kit Designed for the Diversity and Richness of Asian Ethnicities and Ancestral Heritage

SINGAPORE, July 7, 2020 /PRNewswire/ -- Genesis Healthcare Co., Japan's leading genetic testing and research company, today announced the launch of its Asian ancestry focused test kit,GeneLife Generations. The test kit will be officially available to customers from20 July 2020.

2020-07-07 17:32 738

Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells

HOUSTON, July 7, 2020 /PRNewswire/ -- Physician-investigators at Johns Hopkins University Hospital report on the promising data of treatment of COVID-19 induced acute respiratory distress syndrome with allogeneic, cord blood derived T-regulatory (Treg) cell therapy (manufactured by Cellenkos®), p...

2020-07-07 11:15 954

Ortho Clinical Diagnostics Names Joseph M. Busky Chief Financial Officer

RARITAN, New Jersey, July 7, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics backed by The Carlyle Group, announced Joseph M. Busky has joined the Company as Chief Financial Officer, effective July 7, 2020. Busky, who previously served as Chief Financial O...

2020-07-07 05:18 772

Affinity discovers potent SARS-CoV-2 antibodies

MELBOURNE, Australia, July 2, 2020 /PRNewswire/ -- Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for cancer therapeutics, today announces the discovery of potent antibodies with therapeutic potential against COVID-19. In March, Af...

2020-07-02 12:25 1095

Thermo Fisher Scientific Launches New MAS Omni Infectious Disease Quality Controls

FREMONT, California, July 1, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B &...

2020-07-01 20:00 860

Mentice Appoints Thanos Karras as Americas General Manager to Accelerate Group's Growth Strategy

GOTHENBURG, Sweden, July 1, 2020 /PRNewswire/ -- Mentice AB (STO: MNTC) today announced the appointment ofThanos Karras as the company's new General Manager for Americas. Thanos' appointment will play a critical role in supporting Mentice's continual growth strategy and will help accelerate its l...

2020-07-01 16:52 844

RhoVac Marketed in International Press

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...

2020-07-01 15:49 749

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...

2020-07-01 07:30 6377

Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge for Healthcare in the New Normal in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

- QuickFire Challenge calls on innovators to identify and accelerate potential solutions aiming to improve patient care in our post-COVID world. - Awardees will receive up to KRW150,000,000 (approximately US $125,000)[1], residence at the Seoul Bio Hub, and mentorship and coaching from experts at...

2020-07-01 05:30 1587
123456 ... 68